Candel Therapeutics' Upcoming Virtual R&D Event
Candel Therapeutics, Inc. (Nasdaq: CADL), a pioneering clinical-stage biopharmaceutical company, is gearing up for an engaging virtual Research and Development (R&D) event. Scheduled for December 5, 2025, from 11:00 am to 1:45 pm ET, this event promises to showcase the innovative approaches Candel is adopting in the realm of cancer treatment.
What to Expect at R&D Day
The R&D Day will feature a series of insightful presentations and discussions led by Candel’s executive team, seasoned clinical investigators, and notable scientific advisors. Attendees can look forward to a comprehensive overview of the company’s promising viral immunotherapy techniques and the oncology pipeline that stands at the forefront of modern cancer treatment.
Introduction to Candel Therapeutics
Leading the session will be Paul Peter Tak, MD, PhD, FMedSci, Candel’s President and CEO. His insights will set the tone for the entire event, outlining the mission of the company and its commitment to advancing cancer therapies.
Panel Discussion: Immuno-oncology - The Next Wave of Innovation
This panel features a prestigious lineup, including notable experts such as:
- James P. Allison, PhD, Nobel Laureate from the University of Texas MD Anderson Cancer Center
- Carl H. June, MD, from the University of Pennsylvania
- Padmanee Sharma, MD, PhD, also from the University of Texas at MD Anderson
Moderated by Yigal Nochomovitz, PhD from Citi Group, this discussion will focus on cutting-edge advancements in immuno-oncology.
Showcasing CAN-2409
Special attention will be given to CAN-2409, Candel’s frontrunner in immunotherapy. This revolutionary candidate acts as a replication-defective adenovirus that targets tumor cells. By using the herpes simplex virus thymidine kinase (HSV-tk) gene, CAN-2409 converts designated prodrugs to induce immunogenic cell death, prompting the immune system to target cancer cells effectively.
Expert Insights on CAN-2409's Journey
Presentations will detail how CAN-2409’s mechanism is utilized in various cancer types, including newly diagnosed localized prostate cancer. Esteemed professionals like Glen Gejerman, MD from Hackensack University Medical Center and Philip Kantoff, MD from Convergent Therapeutics, will delve into the intricacies of its development process. The contributions of Candel’s Chief Medical Officer, Garrett Nichols, MD, will also lead to discussions about real-world applications and future therapeutic strategies.
Regulatory Milestones
Candel’s Chief Regulatory Officer, Sue Stewart, JD, will outline the strategic roadmap toward obtaining Biologics License Application (BLA) for CAN-2409, ensuring that attendees are informed about the regulatory landscape impacting its approval and adoption.
Exploring CAN-3110 and Future Therapies
Candel is not only relying on CAN-2409 for success. The company’s CAN-3110, a next-generation oncolytic viral immunotherapy, has shown promising results in ongoing clinical trials. It promises dual action; its unique viral properties enable targeted tumor lysis while simultaneously activating the immune system.
Clinical Insights and Breakthrough Results
The recent publication in a reputable journal revealed that CAN-3110 demonstrates a favorable safety profile and potential efficacy in patients with therapy-resistant conditions. This exciting data underlines the ongoing commitment of Candel to innovate and provide significant therapeutic options for patients battling complex forms of cancer.
Candel Therapeutics: A Vision for the Future
At the core of Candel's mission is the focus on off-the-shelf multimodal biologics, designed to evoke potent immune responses tailored to individual patient needs. Recent successes from clinical trials in high-risk cancer patients, like those with pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), indicate the potential of these therapies to change the landscape of cancer treatment significantly.
Candel has built a robust portfolio that not only encourages advancements in cancer therapy but also actively aims to heighten patient quality of life through innovative solutions.
Frequently Asked Questions
What is the significance of Candel Therapeutics’ R&D event?
This event is vital in showcasing the latest advancements and future directions of Candel's cancer therapies, specifically focusing on their unique approaches in immunotherapy.
Who are some key speakers at the R&D Day?
The event will feature experts like Paul Peter Tak, MD, PhD, as well as Nobel Laureate James P. Allison, PhD.
What are CAN-2409 and CAN-3110?
CAN-2409 is a biological immunotherapy candidate addressing localized prostate cancer, while CAN-3110 is a next-generation viral immunotherapy targeting various tumors.
How has CAN-2409 performed in clinical trials?
CAN-2409 has shown promising efficacy and a favorable tolerability profile in trials for several types of cancers, including prostate and lung cancers.
Where can one find more information about Candel Therapeutics?
For detailed information, visit www.candeltx.com.
